Differentiating hereditary from nonhereditary retinoblastoma is now possible overnight, improving early intervention ...

Special circumstances must be considered for plateau dwellers, such as Tibetans, mountaineers, and garrison officers, who are ...

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing ...

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular ...

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...

CVI is a spectrum of visual impairments due to brain abnormalities affecting visual processing pathways, distinct from ocular ...

Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for ...

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating ...

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

This retrospective cohort study was designed to provide further information on the association between BP parameters and VF ...

Sumit Sharma, MD, FASRS ponders to the panel the root cause of improved outcomes with newer agents. The panel then highlights current gaps in measuring visual improvements beyond tools such as the OCT ...